论文部分内容阅读
目的：探讨定量测定胰腺癌患者血清4种肿瘤标志物的临床意义。方法：用蛋白芯片技术定量测定42例正常人、30例胰腺癌和16例胰腺炎患者血清4种肿瘤标志物的变化并对检测效果进行评价。结果：42例正常人血清CA19-9(KU/L)、CA242(KU/I)、CA125(KU/I)和CA153(KU/I)的含量分别为：12．42±10．62、5．73±5．67、5．46±9．53、9．83±9．40；30例胰腺癌患者血清4种肿瘤标志物含量依次为：279．47±402．0、98．23±89．33、167．16±252．49、43．22±99．34；16例胰腺炎患者其含量依次为：53．38±86．38、22．99±51．13、98．67±212．23、4．15±2．13,该蛋白芯片测定的敏感性为70．0%,特异性为89．7%,阳性预测值为77．8%,阴性预测值为88．1%。结论：采用蛋白芯片技术同时测定患者血清中多种肿瘤标志物,对普查肿瘤和临床疗效观察有较好应用价值。
Objective: To investigate the clinical significance of quantitative determination of four tumor markers in patients with pancreatic cancer. Methods: Four kinds of tumor markers of 42 normal subjects, 30 pancreatic cancer patients and 16 pancreatitis patients were quantitatively determined by protein microarray. The detection results were evaluated. Results: The serum levels of CA19-9 (KU / L), CA242 (KU / I), CA125 (KU / I) and CA153 (KU / I) in 42 normal persons were 12.42 ± 10.62 and 5 .73 ± 5.67,5.46 ± 9.53,9.83 ± 9.40. The serum levels of four tumor markers in 30 patients with pancreatic cancer were 279.47 ± 402.0 and 98.23 ± 89.33,167.16 ± 252.49,43.22 ± 99.34; the contents of 16 patients with pancreatitis were: 53.38 ± 86.38,22.99 ± 51.13,98.67 ± 212.23 and 4.15 ± 2.13. The sensitivity of the protein chip assay was 70.0%, the specificity was 89.7%, the positive predictive value was 77.8%, the negative predictive value was 88.1% . Conclusion: Simultaneous determination of a variety of tumor markers in serum by protein chip technology is of great value in the screening of tumors and clinical observation.